HELP Cybin Inc. Common Stock
Healthcare$4.68+1.74%ClosedMarket Cap: $233.5M
As of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.73
P/S
0.00
EV/EBITDA
0.56
DCF Value
$4.34
FCF Yield
-104.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-61.5%
ROA
-45.4%
ROIC
-50.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 null | $0.00 | $-58.5M | $— |
| Q2 null | $0.00 | $-47.0M | $— |
| Q1 null | $0.00 | $-33.5M | $— |
| Q4 null | $0.00 | $-30.6M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$22.00
Target (Median)
$22.00
Target Range
$22.00 - $22.00
0 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-03-02GuggenheimBuy
2025-12-03Canaccord GenuityBuy
2025-11-20HC Wainwright & Co.Buy
2025-11-14Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
0.81
Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder